Protecting the sugar coat on anti-tumor T cells to conceal destruction by tumor microenvironmental landmines
Abstract
Adoptive cellular therapies, highlighted by the burgeoning area of chimeric antigen receptor (CAR) T cell therapy, now offer a promising modality with broad application to both hematological and solid cancers. Anti-CD19 CAR T cell therapy, as an example, is an established treatment option for patients with diffuse large B cell lymphoma (DLBCL). However, despite early successes, therapeutic efficacy is limited due to insufficient in vivo persistence and exposure to immunosuppressive signals within the tumor microenvironment (TME).
Fields of Study & Subjects
Phagocytosis and Immune Regulation
Cancer Research and Treatments
Cancer Immunotherapy and Biomarkers
Publication details
- Journal / source
- Molecular Therapy Oncology
- Publisher
- Elsevier BV
- Volume
- 34
- Issue
- 2
- Pages
- 201202–201202
- Publication date
- 27 April 2026
- Language
- EN